Micro-needling with 5‑fluorouracil versus strong topical steroid for limited vitiligo

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, randomized early-phase trial will enroll about 40 patients with stable vitiligo affecting 10% or less of body surface area and assign them to two treatment groups. One group will receive micro-needling with topical 5‑fluorouracil applied to the lesions every two weeks, while the other will apply 0.05% clobetasol propionate ointment twice daily. Investigators will record baseline photos and VASI scores, then monitor repigmentation, patient satisfaction, and skin side effects over follow-up visits. Safety assessments and adverse event recording will be included to compare tolerability between the two approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients willing to participate in the study
* Patients of age group of 05 -70 years.
* Vitiligo involving less than or equal to 10% body surface area.

Exclusion Criteria:

* Patients using or have used other treatments for vitiligo
* Pregnant women or lactating women
* Patients with unstable vitiligo
* Patients on immunosuppressant medications due to other diseases
* Patients having anemia, immunosuppression, bleeding disorder, taking anticoagulants or anti-platelet drugs or having epilepsy
* Patient having history of keloids or hypertrophic scars
* Patients with history of hypersensitivity to either of the drugs

Where it's running

• CMH Bahawalpur
  Chak Eighty-seven -Twelve Left, Pakistan Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• crisaborole 2% versus tacrolimus 0.1% with light therapy for facial vitiligo

  This study tests whether applying crisaborole 2% ointment can improve stable facial vitiligo in children and adults and whether it is as safe and effective as tacrolimus 0.1% when combined with light therapy.

  Recruiting Phase 3 Cairo University · Cairo · NCT07904910

• Imaging vitiligo lesions with polarized, sub-ultraviolet, and ultraviolet dermoscopy

  This study tests whether advanced light-based skin imaging can reveal details of vitiligo spots in adults more clearly than standard polarized dermoscopy.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07846969

• MH004 Ointment in non-segmental vitiligo: a phase 3 trial

  A 12-month randomized trial tests MH004 ointment to see if it helps facial vitiligo more than a placebo in people aged 12 to 75.

  Recruiting Phase 3 Minghui Pharmaceutical (Hangzhou) Ltd · Beijing, Beijing Municipality · NCT07682506

• NSV: Vitiligo Drug Safety and Effectiveness Registry for Adults and Teens

  This registry tracks adults and teens with nonsegmental vitiligo to see how usual treatments work and how safe they are over time in real-world dermatology care.

  Recruiting CorEvitas · Waltham, Massachusetts · NCT07659418

• D-2570 in Non-Segmental Vitiligo (Phase 2)

  This study tests whether D-2570 can improve skin discoloration in adults with non-segmental vitiligo compared with a placebo.

  Recruiting Phase 2 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07625891

• LY4005130 for adults with non-segmental vitiligo

  This study will test whether intravenous LY4005130 is safe and what side effects it may cause in adults with non-segmental vitiligo.

  Recruiting at 35 sites Phase 2 Eli Lilly and Company · Phoenix, Arizona and 34 other locations · NCT07533019

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.